Drug intelligence / Profile preview

SKF7 + AGS-1

Development stage: Preclinical
Lead developer: Medika Natura
Modality: Small Molecules

Overview

SKF7 + AGS-1 is a preclinical combination therapy developed by Medika Natura, an Indonesian biotechnology company specializing in standardized herbal extracts (phytopharmaceuticals). The combination is being investigated for its potential anti-SARS-CoV-2 activity in the treatment of COVID-19. While specific mechanistic details are limited in public pipeline disclosures, the components are likely derived from standardized botanical sources intended to inhibit viral replication or modulate the host immune response. Medika Natura utilizes a phytopharmaceutical approach to identify and standardize active botanical compounds for therapeutic use.

Other names: SKF7 + AGS-1 combination

Beyond the preview

Go deeper on SKF7 + AGS-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKF7 + AGS-1.

Explore the full profile